MET and non-small cell lung carcinoma: The high expression of MET, as anticipated, significantly reduced the overall survival of patients with EGFR mutated NSCLC (Figure 2A), while this subgroup with elevated MET expression exhibited an enrichment of up‐regulated Wnt signaling (Figure 2B).